Litcius/Paper detail

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Massimo Gentile, Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Luca Laurenti, Marta Coscia, Yair Herishanu, Anna Grazia Recchia, Marzia Varettoni, Roberta Murru, Annalisa Chiarenza, Adalgisa Condoluci, Riccardo Moia, Daniela Pietrasanta, Giacomo Loseto, Ugo Consoli, Ilaria Scortechini, Francesca Maria Rossi, Antonella Zucchetto, Vincenzo Fraticelli, Ernesto Vigna, Cirino Botta, Giovanni Tripepi, G Arrigo, Angela Rago, Ilaria Angeletti, Annalisa Biagi, Ilaria Del Giudice, Riccardo Bomben, Gian Matteo Rigolin, Davide Rossi, Francesco Di Raimondo, Gianluca Gaïdano, Aaron Polliack, Antonio Cuneo, Robin Foà, Valter Gattei

2020Leukemia24 citationsDOI

Topics & Concepts

IbrutinibChronic lymphocytic leukemiaMedicineInternal medicineOncologyRefractory (planetary science)HematologyLeukemiaOverall survivalBiologyAstrobiologyChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentGastrointestinal Tumor Research and Treatment
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study | Litcius